References
- Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–516.
- Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
- Griffiths CEM, van der Walt JM, Ashcroft DM, et al. The global state of psoriasis disease epidemiology: a workshop report. Br J Dermatol. 2017;177:e4–e7.
- Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376:1551–1560.
- Han C, Lofland JH, Zhao N, et al. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2011;10:843–850.
- Levin AA, Gottlieb AB, Au SC. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies. J Drugs Dermatol. 2014;13:848–853.
- Voelker R. Biologic medication for psoriasis. JAMA. 2017;317:1308.
- Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD011535.
- Strober BE, Bissonnette R, Fiorentino D, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016;74:851–861.
- Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276–288.
- Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.
- Novartis Pharmaceuticals Corporation. Cosentyx® (secukinumab) [package insert]. U.S. Food and Drug Administration website. [updated 2016 Jan; cited 2018 Jul 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125504s001s002lbl.pdf
- Eli Lilly and Company. Taltz® (ixekizumab). [package insert]. U.S. Food and Drug Administration website. [updated 2016 Mar; cited 2018 Jul 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125521s000lbl.pdf
- Valeant Pharmaceuticals. Siliq™ (brodalumab). [package insert]. U.S. Food and Drug Administration website. [updated 2017 Feb; cited 2018 Jul 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf
- Janssen Biotech, Inc. Tremfya® (guselkumab). [package insert]. U.S. Food and Drug Administration website. [updated 2017 Jul; cited 2018 Jul 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761061s000lbl.pdf
- Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76:290–298.